ICU
$2.48
SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States.
Intraday
Recent News
SeaStar Medical Holding Corp (ICU) Q3 2025 Earnings Call Highlights: Revenue Surge and ...
SeaStar Medical Holding Corp (ICU) reports a 45% revenue increase and strategic growth in pediatric hospitals, while addressing trial enrollment challenges and revenue variability.
SeaStar Medical (ICU) Q3 2025 Earnings Transcript
Eric Schlorff: Thank you, Jackie, and thank you all for joining us today. Since the beginning of the third quarter, we advanced our business on several fronts that we believe position us well for our future growth.
SeaStar Medical Holding Corp (ICU) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ...
SeaStar Medical Holding Corp (ICU) reports a 370% revenue increase and significant clinical trial progress, despite challenges in customer adoption and operating expenses.
Top Midday Gainers
Plus Therapeutics (PSTV) said Wednesday that the US Food and Drug Administration has cleared its inv
SeaStar Medical Holding Corp (ICU) Q1 2025 Earnings Call Highlights: Revenue Surge and ...
SeaStar Medical Holding Corp (ICU) reports a fourfold revenue increase, new FDA designations, and significant market opportunities in its latest earnings call.